Pembroke Management’s Caris Life Sciences CAI Stock Holding History

Pembroke Management’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.18M	Buy	+299,793	New	+$6.73M	1.14%	32

Other funds holding CAI

Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Pembroke Management's CAI Position: Q3 2026 in Review

Pembroke Management opened a new position in Caris Life Sciences (CAI) in Q3 2026: 299,793 shares worth $9.18M. The stake represents 1.14% of the portfolio and ranks #32 among its holdings.

103 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

Pembroke Management held 299,793 shares of Caris Life Sciences worth $9.18M as of Q3 2026.
Caris Life Sciences was a new Pembroke Management position in Q3 2026.
Caris Life Sciences made up 1.14% of Pembroke Management's portfolio in Q3 2026, its #32 holding.
103 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Pembroke Management's 13F filing for Q3 2026, filed 21 Oct 2026.